Prevention of Constipation in Cancer Patients

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorMarmara University

About this trial

Constipation is the third most common symptom in patients undergoing chemotherapy, with an incidence rate ranging from 31% to 90%. Despite its high prevalence and adverse effects on patients, constipation is often not reported by patients and is not frequently monitored by nurses, resulting in delays in treatment and care. Prolonged constipation can lead to health problems such as fecal impaction/obstruction, hemorrhoids, rectal pain, and intestinal perforation, thereby reducing patients' quality of life. Additionally, increased severity of constipation in cancer patients may lead to the interruption or complete cessation of chemotherapy. Therefore, it is essential to monitor and assess patients for the risk of developing constipation and to implement an effective nursing care protocol.

Abdominal massage is an approach that increases peristalsis, i.e., digestive system movement, by altering intra-abdominal pressure, thereby reducing the severity of constipation.

Eligibility criteria

Qualifiers

18 years of age or older,

Receiving chemotherapy for breast cancer or lung cancer that causes constipation

Patients who received at least one cycle of chemotherapy and experienced chemotherapy-associated constipation within five days of treatment (stool type 1 or 2 according to the Bristol Stool Scale)

Volunteers who are willing to participate in the research, can communicate, and can read and write,

Disqualifiers

Patients with stool type 3, 4, 5, 6 and 7 points according to the Bristol Stool Scale

Trial design

Treatments tested in this trial

  • Abdominal Massage

Treatment groups

146 Participants
are divided into 2 treatment groups

Sponsors and collaborators

Marmara University

Lead sponsor

Istanbul University - Cerrahpasa

Collaborator